Please assess the completion status of the following clinical trial:

Trial Title: Controling Intestinal Colonization With Extended Spectrum ß-Lactamase Producing Enterobacteriaceae ESBL-E

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fecal colonization with ESBL-E, as confirmed by a positive sample (rectal swab or stool sample) obtained within 14 days prior to study enrolment~* Ongoing or scheduled immunosuppression:~  * allogeneic or autologous hematopoietic stem cell transplantation within 14 days after enrollment or~ * chemotherapy with an expected duration of chemotherapy-associated neutropenia of at least 7 days within 14 days after enrollment or~ * solid organ transplantation within 14 days after enrollment or~ * administration of high-dose corticosteroids or other immunosuppressants for acute rejection of a solid organ transplant or for graft versus host disease after stem cell transplantation~* Age of at least 18 years~* Subject is not legally incapacitated~* Written informed consent from the trial subject has been obtained~Exclusion Criteria:~* Current or scheduled administration of ESBL-E active antibiotic treatment after receipt of the most recent sample showing intestinal ESBL-E colonization and within 10 days after randomization~* Planned selective digestive tract decolonization within 42 days following randomization~* Known hypersensitivity or allergy to any of the components of the study treatment~* Moderate or severe liver dysfunction at baseline, defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels greater than three times the upper limit of normal (ULN), AND a total bilirubin level greater than two times the ULN~* Serum creatinine \> 2 x the upper limit of the ULN~* Inability to take oral medication~* Concurrent participation in another clinical trial with an investigational drug is not permitted, unless the drug under study is related to the treatment of the underlying condition or a transplantation~* Current pregnancy or nursing period~* In female study participants, failure to use highly-effective contraceptive methods. The following contraceptive methods with a Pearl Index lower than 1% are regarded as highly-effective:~  * Oral hormonal contraception ('pill')~ * Dermal hormonal contraception~ * Vaginal hormonal contraception (NuvaRing®)~ * Contraceptive plaster~ * Long-acting injectable contraceptives~ * Implants that release progesterone (Implanon®)~ * Tubal ligation (female sterilization)~ * Intrauterine devices that release hormones (hormone spiral)~ * Double barrier methods This means that the following are not regarded as safe: condom plus spermicide, simple barrier methods (vaginal pessaries, condom, female condoms), copper spirals, the rhythm method, basal temperature method, and the withdrawal method (coitus interruptus).~* Patient has any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the patient participating in the study, would make it unlikely for the patient to complete the study, or would confound the results of the study~* Persons with any kind of dependency on the investigator or employed by the sponsor or investigator~* Persons held in an institution by legal or official order

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ESBL eradication regimen (Type: ACTIVE_COMPARATOR): Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
- Placebo ESBL eradication (Type: PLACEBO_COMPARATOR): Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).